Literature DB >> 16891445

Preventing fragility hip fracture in high risk groups: an opportunity missed.

E W K Peng1, S Elnikety, N C Hatrick.   

Abstract

OBJECTIVE: The national guideline recommends selective case finding as the main strategy by identification of high risk people. This study assessed whether high risk patients were identified before their presentation with fragility fracture.
METHODS: A prospective study for 3.5 consecutive months on patients with low energy hip fractures to Brighton and Sussex University Hospital NHS Trusts, which serves a population of 460,000. Data were collected by interview using standardised form, medical record review, and communication with family physicians. Definition of high risk: (1) untreated hypogonadism (2) corticosteroid users (3) disorders with increased bone loss (4) previous fragility fractures.
RESULTS: 98 patients were admitted with hip fracture. Thirty nine (40%) had at least one high risk factor. High risk patients (7 of 39, 18%) were no more likely to receive prophylaxis compared with patients without high risk factor (5 of 59, 8%) (p = 0.21). Previous fragility fracture (23) was the commonest risk factor followed by disorders with increased bone loss (10), premature menopause (10), and corticosteroid users (5). Fifteen patients (15%) had susceptibility to frequent falls and two had maternal history of osteoporosis. The proportion of treated patients were 20% (2 of 10) in premature menopause, 10% (1 of 10) in diseases with secondary osteoporosis, 13% (3 of 23) in previous fragility fracture, and 80% (4 of 5) in corticosteroid users (p = 0.01)
CONCLUSION: Prevention of hip fracture is still inadequate in high risk patients. Discrepancy seemed to exist in treatment frequency among different high risk groups suggesting that emphasis on prevention of osteoporosis has not been reinforced in all people at risk.

Entities:  

Mesh:

Year:  2006        PMID: 16891445      PMCID: PMC2585701          DOI: 10.1136/pgmj.2005.044370

Source DB:  PubMed          Journal:  Postgrad Med J        ISSN: 0032-5473            Impact factor:   2.401


  14 in total

Review 1.  Preventing fractures in elderly people.

Authors:  Anthony D Woolf; Kristina Akesson
Journal:  BMJ       Date:  2003-07-12

2.  Prevention of spinal osteoporosis in oophorectomised women.

Authors:  R Lindsay; D M Hart; C Forrest; C Baird
Journal:  Lancet       Date:  1980-11-29       Impact factor: 79.321

3.  Risk factors for hip fracture in men from southern Europe: the MEDOS study. Mediterranean Osteoporosis Study.

Authors:  J Kanis; O Johnell; B Gullberg; E Allander; L Elffors; J Ranstam; J Dequeker; G Dilsen; C Gennari; A L Vaz; G Lyritis; G Mazzuoli; L Miravet; M Passeri; R Perez Cano; A Rapado; C Ribot
Journal:  Osteoporos Int       Date:  1999       Impact factor: 4.507

4.  Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study.

Authors:  M C Chapuy; R Pamphile; E Paris; C Kempf; M Schlichting; S Arnaud; P Garnero; P J Meunier
Journal:  Osteoporos Int       Date:  2002-03       Impact factor: 4.507

Review 5.  Epidemiology and outcomes of osteoporotic fractures.

Authors:  Steven R Cummings; L Joseph Melton
Journal:  Lancet       Date:  2002-05-18       Impact factor: 79.321

6.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

Authors:  D M Black; S R Cummings; D B Karpf; J A Cauley; D E Thompson; M C Nevitt; D C Bauer; H K Genant; W L Haskell; R Marcus; S M Ott; J C Torner; S A Quandt; T F Reiss; K E Ensrud
Journal:  Lancet       Date:  1996-12-07       Impact factor: 79.321

7.  Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial.

Authors:  S R Cummings; D M Black; D E Thompson; W B Applegate; E Barrett-Connor; T A Musliner; L Palermo; R Prineas; S M Rubin; J C Scott; T Vogt; R Wallace; A J Yates; A Z LaCroix
Journal:  JAMA       Date:  1998 Dec 23-30       Impact factor: 56.272

8.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.

Authors:  Jacques E Rossouw; Garnet L Anderson; Ross L Prentice; Andrea Z LaCroix; Charles Kooperberg; Marcia L Stefanick; Rebecca D Jackson; Shirley A A Beresford; Barbara V Howard; Karen C Johnson; Jane Morley Kotchen; Judith Ockene
Journal:  JAMA       Date:  2002-07-17       Impact factor: 56.272

9.  Effects of vitamin D and calcium supplementation on falls: a randomized controlled trial.

Authors:  Heike A Bischoff; Hannes B Stähelin; Walter Dick; Regula Akos; Margrith Knecht; Christian Salis; Matthias Nebiker; Robert Theiler; Michael Pfeifer; Bettina Begerow; Robert A Lew; Martin Conzelmann
Journal:  J Bone Miner Res       Date:  2003-02       Impact factor: 6.741

10.  A randomised, controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: The Nottingham Neck of Femur (NONOF) Study.

Authors:  Rowan H Harwood; Opinder Sahota; Kay Gaynor; Tahir Masud; David J Hosking
Journal:  Age Ageing       Date:  2004-01       Impact factor: 10.668

View more
  4 in total

Review 1.  Fracture Liaison Services in the United Kingdom.

Authors:  Paul J Mitchell
Journal:  Curr Osteoporos Rep       Date:  2013-12       Impact factor: 5.096

2.  Hypovitaminosis D as a risk factor of hip fracture severity.

Authors:  M Larrosa; A Gomez; E Casado; M Moreno; I Vázquez; C Orellana; E Berlanga; J Ramon; J Gratacos
Journal:  Osteoporos Int       Date:  2011-03-11       Impact factor: 4.507

3.  Utilization of inpatient care before and after hip fracture: a population-based study.

Authors:  E Lönnroos; H Kautiainen; R Sund; P Karppi; S Hartikainen; I Kiviranta; R Sulkava
Journal:  Osteoporos Int       Date:  2008-09-23       Impact factor: 4.507

4.  For the first fracture to be the last.

Authors:  Bernardo Stolnicki; Lindomar Guimarães Oliveira
Journal:  Rev Bras Ortop       Date:  2016-02-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.